About InnAVasc
InnAVasc is a company based in Durham (United States) founded in 2013 was acquired by W. L. Gore & Associates in August 2022.. InnAVasc has raised $3.34 million across 12 funding rounds from investors including W. L. Gore & Associates, Duke University and HHS. InnAVasc offers products and services including InnAVasc Arteriovenous Graft. InnAVasc operates in a competitive market with competitors including TISSIUM, Laminate Medical, Vivasure Medical, Cardival Medical and Saranas, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Innavasc Medical, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.34 M (USD)
in 12 rounds
-
Latest Funding Round
$1 M (USD), Debt – Conventional
Nov 09, 2021
-
Investors
W. L. Gore & Associates
& 5 more
-
Employee Count
Employee Count
-
Acquired by
W. L. Gore & Associates
(Aug 16, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InnAVasc
InnAVasc offers a comprehensive portfolio of products and services, including InnAVasc Arteriovenous Graft. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Reduces complications and bleeding during hemodialysis treatments.
Unlock access to complete
Unlock access to complete
Funding Insights of InnAVasc
InnAVasc has successfully raised a total of $3.34M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $1 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Debt – Conventional — $1.0M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Debt – Conventional - InnAVasc | Valuation |
investors |
|
| Apr, 2020 | Amount | Debt – Conventional - InnAVasc | Valuation |
investors |
|
| Apr, 2020 | Amount | Grant - InnAVasc | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in InnAVasc
InnAVasc has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include W. L. Gore & Associates, Duke University and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by the US Government
|
Founded Year | Domain | Location | |
|
Biotech startups are incubated and funded in North Carolina.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by InnAVasc
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - InnAVasc
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Innavasc Comparisons
Competitors of InnAVasc
InnAVasc operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TISSIUM, Laminate Medical, Vivasure Medical, Cardival Medical and Saranas, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vascular sealants for open surgery are developed by TISSIUM.
|
|
| domain | founded_year | HQ Location |
AV fistula maturation and patency are supported by VasQ device.
|
|
| domain | founded_year | HQ Location |
Bioabsorbable implants and delivery systems for arteriotomy closure are developed.
|
|
| domain | founded_year | HQ Location |
A device for vascular access management is developed.
|
|
| domain | founded_year | HQ Location |
A device is developed for detecting internal bleeding during catheterization.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine products are developed for orthopedic and cardiovascular applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Innavasc
Frequently Asked Questions about InnAVasc
When was InnAVasc founded?
InnAVasc was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is InnAVasc located?
InnAVasc is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is InnAVasc a funded company?
InnAVasc is a funded company, having raised a total of $3.34M across 12 funding rounds to date. The company's 1st funding round was a Grant of $799.94K, raised on Oct 01, 2014.
What does InnAVasc do?
InnAVasc Medical was founded in 2013 by Duke University surgeoninventors and is located in Durham, United States. Medical devices focused on vascular access for hemodialysis are designed and developed by the company. The initial product consists of a synthetic graft featuring two penetration-resistant chambers, one for outbound blood flow and one for inbound, each with self-sealing windows for needle punctures. FDA 510(k) clearance was granted in December 2014.
Who are the top competitors of InnAVasc?
InnAVasc's top competitors include TISSIUM, Vivasure Medical and Cardival Medical.
What products or services does InnAVasc offer?
InnAVasc offers InnAVasc Arteriovenous Graft.
Who are InnAVasc's investors?
InnAVasc has 6 investors. Key investors include W. L. Gore & Associates, Duke University, HHS, NCBiotech, and America’s Seed Fund.